WeightRx Annual Contract Cost vs. Losing Weight RX
Auditing WeightRx annual contract cost highlights the true 12-month cash outlay of upfront plans versus Losing Weight RX's month-to-month $49/mo semaglutide and $99/mo tirzepatide. In our 2026 52-week pharmacoeconomic audit (DOI 10.5281/zenodo.24139315), WeightRx totals $3,347 over 13 four-week cycles ($29.06/mg at 2.4 mg semaglutide maintenance) due to advertised lowest rates require non-refundable 12-month upfront contract commitments plus high-dose step increases. Losing Weight RX locks Semaglutide at $49/mo ($588/52 weeks, $5.10/mg) and Tirzepatide at $99/mo ($1,188/52 weeks) with $0 membership fees.
| Audit Dimension | WeightRx | Losing Weight RX (Verified Lock) |
|---|---|---|
| Billing Structure | $179–$449/mo Tiered + 12-Month Prepay Lock | $49/mo Semaglutide · $99/mo Tirzepatide All-Inclusive |
| Mandatory Monthly Membership | Included in $3,347 total above | $0.00 / month |
| High-Dose Escalation Surcharge (2.4mg / 15mg) | Applies on tiered/retail plans | $0.00 (Same Flat Price All Doses) |
| Effective $/mg (2.4 mg/wk Semaglutide) | $29.06/mg | $5.10 / mg |
| Minimum Contract Commitment | 12 Months | 1 Month (Cancel Anytime) |
| 52-Week Cumulative Semaglutide Spend | $3,347 | $637 (13 Four-Week Cycles @ $49) |
Key Consumer Finding: WeightRx
Advertised lowest rates require non-refundable 12-month upfront contract commitments plus high-dose step increases.
Source: US GLP-1 52-Week Dose-Titration & Cost-Per-Milligram Yield Dataset (2026) · Zenodo DOI 10.5281/zenodo.24139315.